Managing Patients with HFrEF Post-Discharge: Discussion of the Latest Evidence

In 2021, new practice guidelines, updated clinical pathways, and a universal definitions and classification document were released to help clinicians better diagnose, stage, and manage patients with heart failure (HF). The recommendations include direction on sequencing foundational therapies and integrating the latest FDA-approved additions to the HF armamentarium – SGLT2 inhibitors and an oral sGC stimulator–for patients with HF with reduced ejection fraction (HFrEF).

In this first of two episodes in the CMEOCast HF podcast series, an expert faculty, including a member of the writing committee for several of the new guidelines, provides insightful perspectives on implementing the new recommendations in practice, including risk stratification, staging/classification, the role of biomarkers, therapeutic sequencing, relevant guidelines and study results. Additionally, faculty discuss helpful apps available for risk stratification and treatment decision-making support.

Learning Objectives
At the end of this CME/CE activity, participants should be able to:
- Integrate a risk stratification tool into practice for assessment of patients with HFrEF.
- Implement treatment strategies for HFrEF that reflect updated guidelines and study results.